Coats on for Starpharma
Tuesday, 09 September, 2008
Starpharma [ASX: SPL] has licensed the marketing rights to its VivaGel coated condom to SSL International, owners of the market-leading Durex condom brand.
Under the agreement, SSL has been granted the right to marketing the VivaGel condom in most of the world, including Europe and the US.
The agreement could be worth at least $100 million in royalties, milestone payments and development support to Starpharma.
Starpharma is continuing to develop VivaGel as an applicator-delivered vaginal product designed to help women protect themselves from HIV and genital herpes.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
